Sandbox Reserved 1161: Difference between revisions

Revision as of 02:31, 30 March 2016 view source Connor Coatney (talk \| contribs) 74 edits No edit summary ← Older edit		Revision as of 02:46, 30 March 2016 view source Connor Coatney (talk \| contribs) 74 edits No edit summary Newer edit →
Line 18:		Line 18:
	In the 7 transmembrane domain (TMD), <scene name='72/721532/Mavoglurant_in_pocket/4'>Mavoglurant</scene> is in the 7TM domain pocket. Also, the lysozyme is attached to the intercellular region of the TMD.		In the 7 transmembrane domain (TMD), <scene name='72/721532/Mavoglurant_in_pocket/4'>Mavoglurant</scene> is in the 7TM domain pocket. Also, the lysozyme is attached to the intercellular region of the TMD.

	The variation can be seen in positioning of alpha helices. Class C has seemingly less space for mavoglurant to enter compared to Class A and F (Wu). The binding of mavoglurant is seen to be varied in different locations due to helix position (Dore).		The variation can be seen in positioning of alpha helices. Class C has seemingly less space for [https://fragilex.org/2014/research/news-reports-and-commentaries/novartis-announces-results-of-mavoglurant-mglur5-afq056-clinical-trials-and-the-conclusion-of-the-long-term-extension-study/ mavoglurant] to enter compared to Class A and F (Wu). The binding of mavoglurant is seen to be varied in different locations due to helix position (Dore).

Navigation menu